A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

NCT05224609 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate Hepatic Impairment
Severe Hepatic Impairment
Healthy Volunteers

Interventions

DRUG: Lorlatinib

Sponsor

Pfizer